Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Weaver BR, Mumma JM, Parmar S, Morgan JS, Ghassemian G, Burke KB, Gannon PR, MacKay RE, Berryhill BA, Lee L. Sequencing patient care tasks as an infection prevention practice. Poster presented at the 67th the Human Factors and Ergonomics Society Annual Meeting; October 2023. Washington, DC. [abstract] Proc Hum Factors Ergon. 2023 Oct 25; 67(1):1900-4. doi: 10.1177/21695067231192931
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008 Mar 1;49(3):446-54.
McAfee AT, Chilcott KE, Johannes CB, Hornbuckle K, Hauser WA, Walker AM. The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses. Epilepsia. 2007 Jun 1;48(6):1075-82.
Arana A. A North American Registry for epilepsy and pregnancy, a unique public/private partnership of health surveillance. Epilepsia. 1998 Jul;39(7):793-8.
Dalla Bernardina B, Fontana E, Vigevano F, Fusco L, Torelli D, Galeone D, Buti D, Ciancheti C, Gnanasakthy A, Iudice A. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia. 1995 Jul;36(7):687-91.